IMRICOR SIGNS JOINT DEVELOPMENT AGREEMENT WITH ADIS FOR AI MODULES IN NORTHSTAR

Highlights:

- **Artificial Intelligence (AI) modules developed by ADIS SA (ADIS) of Lausanne, Switzerland to be incorporated into Imricor's NorthStar 3D mapping system**
- **First AI module to deliver automatic segmentation of cardiac chambers, expected to further reduce procedure times**
- **NorthStar user interface to be incorporated into ADIS's ARTS iCMR procedure simulator platform**

27 November 2023 – Minneapolis, MN United States (**28 November 2023** – Melbourne, Australia) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) is pleased to advise that it has signed a Joint Development Agreement (**JDA**) with ADIS SA (**ADIS**) of Lausanne, Switzerland (https://www.adis-sa.com).

Under the terms of the JDA, Imricor and ADIS will collaborate to incorporate Artificial Intelligence (AI) modules developed by ADIS within Imricor's NorthStar 3D mapping system, starting with automatic segmentation of cardiac chambers from MRI images. Automatic segmentation is expected to save time during iCMR procedures.

In addition, the companies will collaborate to incorporate NorthStar's user interface into ADIS's ARTS iCMR procedure simulator platform (**ARTS**) (https://www.adis-sa.com/product-arts/). ARTS is a simulator platform that allows a user to guide Imricor's Vision-MR Ablation Catheters within a physical tabletop device and view the catheter's simulated location relative to anatomy derived from real MRI images within the ARTS user interface. Initially, ADIS developed their own user interface for ARTS; however, the JDA paves the way for the ARTS user environment to become the NorthStar user environment.



NorthStar 3D mapping System
Imricor



ARTS iCMR Procedure Simulator Platform
ADIS

Imricor's Chair and CEO, Steve Wedan, commented: *"We have been working with the highly talented people at ADIS for several years and are thrilled to advance our partnership to the next level with this Joint Development Agreement.*

"One of our primary goals is to leverage ADIS's extensive expertise in AI development to bring it into NorthStar, such that we can increasingly deliver the power and value of MR imaging to our physicians performing ablations in the iCMR lab with Imricor products.

"Another goal of the JDA is to integrate the NorthStar user environment into the ARTS iCMR procedure simulator platform. As we have highlighted in the past, we intend for NorthStar to be the central hub of every procedure performed in the iCMR lab with Imricor catheters. Therefore, it makes sense that NorthStar should be the environment experienced by users simulating those same iCMR procedures. In the end, we want the user experience within the ARTS simulator to be as close as possible to the experience in the real iCMR lab, thereby reducing training time for iCMR procedures, allowing for patient-specific procedure planning and simulation prior to live procedures, and making the initial simulated experience of performing an ablation guided by MRI more easily accessible to more physicians.

"This is yet another way we are demonstrating our commitment to building our leadership position in the field of iCMR-guided interventions."

Under the terms of the JDA, each company will collaborate at their own expense, and the JDA will remain in effect until terminated by either party, upon 60 days written notice.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

Media and Investor Relations Contact:

Simon Hinsley
simon@nwrcommunications.com.au
+61 401 909 653

About ADIS

ADIS SA, headquartered in Lausanne, Switzerland, inspires and designs products and software based on innovative technologies to create augmented reality solutions dedicated to supporting various operations of medical staff.

Learn more at https://www.adis-sa.com.

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in Australia, the U.S., and the Middle East.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.